YOU are invited to Perpetual Life Thursday, December 18th In Person or Online! Please share this notice with all those you LOVE! Our doors open at 6:00 PM…
Get the latest international news and world events from around the world.
New study suggests a way to rejuvenate the immune system
As people age, their immune systems decline. But a new study suggests a way to rejuvenate immune function: Stimulating the liver to produce some signals ordinarily generated by the thymus can reverse age-related declines in T-cell populations.
MIT and Broad Institute researchers found a way to overcome age-related immune system decline by temporarily programming liver cells to take over the maturation of T cells. Using mRNA, the researchers were able to rejuvenate the immune system, in a study of mice.
Snakes’ mind-bending ‘heat vision’ inspires scientists to build a 4K imaging system that could one day fit into your smartphone
Scientists in China have developed a first-of-its-kind artificial imaging system inspired by snakes that are able to “see” heat coming off their prey in total darkness. The sensor captures ultra-high-resolution infrared (IR) images in 4K resolution (3,840 × 2,160 pixels) — matching the image quality of the iPhone 17 Pro’s camera.
Any object with a temperature above absolute zero (−460 degrees Fahrenheit or-273 degrees Celsius) emits some electromagnetic radiation. For normal body heat, this has a wavelength in the IR range. The human eye can only pick up shorter wavelengths that are in the visible light range.
Extreme ultraviolet lithography
(EUVL, also known simply as EUV) is a technology used in the semiconductor industry for manufacturing integrated circuits (ICs). It is a type of photolithography that uses 13.5 nm extreme ultraviolet (EUV) light from a laser-pulsed tin (Sn) plasma to create intricate patterns on semiconductor substrates.
Thrombolysis With Tenecteplase for Minor Disabling Stroke: Secondary Analysis of the TEMPO-2 Randomized Clinical Trial
A secondary analysis of the TEMPO-2 RCT found no significant improvement in outcomes for minor ischemic stroke patients treated with intravenous tenecteplase, regardless of the presence of disabling deficits.
Question Did outcomes following intravenous tenecteplase for minor ischemic stroke vary based on the presence of disabling deficits?
Findings In this secondary analysis of the TEMPO-2 randomized clinical trial including 884 patients with minor ischemic stroke and proven intracranial occlusion, both patients with and without disabling deficits defined according to US National Institutes of Health Stroke Scale (NIHSS)–based criteria showed a neutral treatment effect from intravenous tenecteplase, with no significant effect modification.
Meaning Current definitions of disabling stroke did not modify the neutral treatment effect of intravenous tenecteplase in patients with minor stroke and intracranial occlusion.
